Ardena announced that it has acquired ChemConnection. Originating from Organon and Merck Sharp & Dohme (MSD) in 2012, Netherlands-based ChemConnection has rapidly evolved to become a respected contract services provider serving biotechs and mid-sized pharmaceutical companies on a global scale.
This announcement follows a series of acquisitions by Belgium-headquartered Ardena and is part of its strategy to form a leading integrated drug development company and reach the €30m sales mark this year.
Harry Christiaens, CEO of Ardena, said: "This acquisition is a major step in the execution of our wider strategy to become one of Europe’s leading one-source-contractors for the development of clinical supplies."
"Until today, Ardena was primarily focused on pharmaceutical development and manufacturing of drug products. With the acquisition of ChemConnection we strengthen our offering with complementary drug substance services. Moreover, the team in Oss, the Netherlands, is globally reputed for its nanomedicine expertise enabling the targeted delivery of complex small molecules and biomolecules.”
Gerjan Kemperman, CEO of ChemConnection, said: “Joining Ardena enables us to serve our customers with much broader services covering their API, drug product, regulatory CMC and bioanalysis requirements. In addition, together we can benefit from synergies that will boost the growth of our business.”
